TOP TEN perturbations for 1553142_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553142_at
Selected probe(set): 228937_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553142_at (228937_at) across 6537 perturbations tested by GENEVESTIGATOR:
doxorubicin study 3 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):5.8644085Number of Samples:2 / 2
Experimental | doxorubicin study 3 |
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code: | |
Control | untreated MCF-7 cell sample |
MCF-7 cells untreated. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):5.83428Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):4.6375713Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.533991Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
PMA study 2 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.3887205Number of Samples:3 / 2
Experimental | PMA study 2 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
IL-4; GM-CSF study 1 (early) / untreated monocyte sample
Relative Expression (log2-ratio):4.2618027Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (early) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):-4.0663905Number of Samples:2 / 3
Experimental | glioma study 16 (LN-18) |
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.6983013Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
adefovir study 1 (50uM) / vehicle (DMSO) treated HepG2 sample
Relative Expression (log2-ratio):3.6869373Number of Samples:3 / 21
Experimental | adefovir study 1 (50uM) |
HepG2 cells treated with compound: adefovir (50uM; CAS no.:106941-25-7) for 24 hours. Adefovir is non-hepatotoxic. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:--- | |
Control | vehicle (DMSO) treated HepG2 sample |
HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):3.5898771Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |